Exact Sciences completed its acquisition of Ashion Analytics, according to an April 14 announcement.
Exact Sciences first announced the acquisition in February. The acquisition will incorporate Ashion's team and help advance Exact Sciences' precision oncology portfolio. It also puts Exact Sciences into a research collaboration with the Translational Genomics Research Institute and City of Hope to develop differentiated minimal residual disease-testing capabilities.
"With Ashion, we've added a talented team, a CLIA-certified and CAP-accredited lab, deep sequencing capabilities, and one of the most comprehensive genomic cancer tests available on the market today with GEM ExTra," Exact Sciences CEO and Chair Kevin Conroy said. "This expertise will be integral in helping us extend our leadership in precision oncology and in serving more patients across the cancer continuum, including therapy selection and minimal residual disease testing."